secwatch.observer — SEC 8-K summary
======================================

Issuer:     Passage BIO, Inc. (PASG)
CIK:        0001787297
Form:       8-K
Filed at:   2023-03-06T23:59:59+00:00
Accession:  0001558370-23-002831
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Passage Bio reports FY2022 net loss of $136.1M; cash runway into H1 2025; clinical updates for GM1 and FTD
--------------------------------------------------------------------------------

- Cash and marketable securities $189.6M at Dec 31, 2022, down from $315.8M; runway into first half of 2025.
- FY2022 net loss $136.1M ($2.50 per share) vs $185.4M ($3.48) in 2021; R&D expenses $86.1M.
- PBGM01 for GM1 gangliosidosis: interim data shows biological effect; plan to dose first patient at higher dose in H2 2023.
- upliFT-D trial for FTD-GRN: enrollment ongoing; initial safety/biomarker data from Cohort 1 expected H2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787297/000155837023002831/0001558370-23-002831-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787297/000155837023002831/pasg-20230306x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-002831

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer